Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

CD4+ T cells are crucial in generating and sustaining immune responses. They orchestrate
and fine-tune mammalian innate and adaptive immunity through cell-based interactions and …

Genome editing technologies have seen remarkable progress in recent years, enabling
precise regulation of exogenous and endogenous genes. These advances have been …

Most patients treated with US Food and Drug Administration (FDA)–approved chimeric
antigen receptor (CAR) T cells eventually experience disease progression. Furthermore …

Single-nucleotide variants (SNVs) in key T cell genes can drive clinical pathologies and
could be repurposed to improve cellular cancer immunotherapies. Here, we perform …

CAR-T cell therapy, a novel immunotherapy, has made significant breakthroughs in clinical
practice, particularly in treating B-cell-associated leukemia and lymphoma. However, it still …

Although chimeric antigen receptor (CAR) T cell therapies have demonstrated promising
clinical outcomes, durable remissions remain limited. To extend the efficacy of CAR T cells …

Substantial progress in understanding T cell signalling, particularly with respect to T cell co-
receptors such as the co-stimulatory receptor CD28, has been made in recent years. This …

This review critically examines the evolving landscape of chimeric antigen receptor (CAR) T-
cell therapy in treating solid tumors, with a particular focus on the metabolic challenges …

Chimeric antigen receptor (CAR) T cells express antigen-specific synthetic receptors, which
upon binding to cancer cells, elicit T cell anti-tumor responses. CAR T cell therapy has …